Literature DB >> 10887123

Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells.

C Lehmann1, M Zeis, N Schmitz, L Uharek.   

Abstract

Exocytosis of perforin, subsequent binding of perforin to the target cell membrane, and formation of lytic pores form an important pathway involved in the induction of tumor cell death by cytotoxic effector cells. Here we describe a novel escape mechanism employed by tumor cells to protect themselves from granule-mediated cell death: We were able to demonstrate that the resistance of the human leukemia cell line ML-2 to natural killer (NK)-cell-mediated killing is not caused by impaired NK-cell activation but by resistance against effector molecules contained in the granules of cytotoxic cells. No resistance was observed against other pore-forming agents like complement and streptolysin O. By using the NK-susceptible leukemia cell line K562, we could show that the induction of cell death by cytotoxic granules can be blocked completely by anti-perforin antibodies, indicating that perforin is essentially involved in this process. Flow cytometric data revealed that an impaired binding of perforin on the tumor cell membrane is mainly responsible for target cell resistance, because perforin turned out to bind well on K562 cells but is not able to attach to the surface of ML-2 cells. After impaired binding of perforin was identified as a potential mechanism of tumor cell resistance, leukemia cells from 6 patients with acute myeloid leukemia (AML) were examined. As predicted, AML cells that failed to bind perforin on their surface demonstrated complete resistance toward NK-cell-mediated cytotoxicity. Thus, perforin resistance could represent an important tumor escape mechanism that should be considered when cytotoxic effector cells are used for cellular immunotherapy. (Blood. 2000;96:594-600)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10887123

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy.

Authors:  Salem Chouaib
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

Review 2.  Effector lymphocytes in islet cell autoimmunity.

Authors:  Pere Santamaria
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

3.  Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia.

Authors:  J K Orleans-Lindsay; L D Barber; H G Prentice; M W Lowdell
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

4.  MicroRNA-29b mediates altered innate immune development in acute leukemia.

Authors:  Bethany L Mundy-Bosse; Steven D Scoville; Li Chen; Kathleen McConnell; Hsiaoyin C Mao; Elshafa H Ahmed; Nicholas Zorko; Sophia Harvey; Jordan Cole; Xiaoli Zhang; Stefan Costinean; Carlo M Croce; Karilyn Larkin; John C Byrd; Sumithira Vasu; William Blum; Jianhua Yu; Aharon G Freud; Michael A Caligiuri
Journal:  J Clin Invest       Date:  2016-10-24       Impact factor: 14.808

5.  The human cytomegalovirus protein UL16 mediates increased resistance to natural killer cell cytotoxicity through resistance to cytolytic proteins.

Authors:  Jenny Odeberg; Helena Browne; Sunil Metkar; Christopher J Froelich; Lars Brandén; David Cosman; Cecilia Söderberg-Nauclér
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

Review 6.  Immune system: a double-edged sword in cancer.

Authors:  Bodduluru Lakshmi Narendra; Kasala Eshvendar Reddy; Saladi Shantikumar; Sistla Ramakrishna
Journal:  Inflamm Res       Date:  2013-07-19       Impact factor: 4.575

7.  Relevance of target cell-induced apoptosis as mechanism of resistance against natural killer cells.

Authors:  Justin Hasenkamp; Andrea Borgerding; Gerald Wulf; Norbert Schmitz; Lorenz Truemper; Bertram Glass
Journal:  Ann Hematol       Date:  2009-10-13       Impact factor: 3.673

8.  Switch from perforin-expressing to perforin-deficient CD8(+) T cells accounts for two distinct types of effector cytotoxic T lymphocytes in vivo.

Authors:  Avihai Meiraz; Orit Gal Garber; Shaul Harari; David Hassin; Gideon Berke
Journal:  Immunology       Date:  2009-09       Impact factor: 7.397

Review 9.  Role of immunotherapy in stem cell transplantation.

Authors:  Sally Arai; Hans G Klingemann
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

10.  Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.

Authors:  Kathryn Hall; Karen J Scott; Ailsa Rose; Michael Desborough; Kevin Harrington; Hardev Pandha; Christopher Parrish; Richard Vile; Matt Coffey; David Bowen; Fiona Errington-Mais; Alan A Melcher
Journal:  Biores Open Access       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.